Development of new antitumor compounds acting on cancer stem cells, with the support of the “la Caixa” Foundation

Bioengineering

Cancer stem cells (CSCs) are a subpopulation of tumor cells primarily responsible for tumor initiation, metastasis and therapy resistance. Many chemotherapies used to fight cancer fail to eliminate CSCs in part because of their high plasticity, a property used by CSCs to adapt, resist treatment and continue to spread. However, CSCs depend on mitochondrial respiration to survive and evade the immune system’s defenses, which the investigators believe represents a metabolic Achilles’ heel of these cells.

Credit: Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS)

Cancer stem cells (CSCs) are a subpopulation of tumor cells primarily responsible for tumor initiation, metastasis and therapy resistance. Many chemotherapies used to fight cancer fail to eliminate CSCs in part because of their high plasticity, a property used by CSCs to adapt, resist treatment and continue to spread. However, CSCs depend on mitochondrial respiration to survive and evade the immune system’s defenses, which the investigators believe represents a metabolic Achilles’ heel of these cells.

The group led by Prof. José Luis Mascareñas at the Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS) has been working together with the team led by Dr. Bruno Sainz at the Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM CSIC-UAM) on the identification of new compounds that alter and modulate mitochondrial respiration in cancer stem cells, decreasing their potential to promote and regenerate tumors. Results obtained so far in pancreatic CSCs and in preclinical models of patient-derived xenografts demonstrate potent antitumor activity, and in vivo studies suggest low toxicity associated with these metal-like compounds.

This project has just received a new financial boost through the CaixaResearch Consolidate program of the “la Caixa” Foundation, a call that supports innovative and mature projects in the area of health, and which have a solid valorization plan. The new grant will allow the team to carry out a series of additional studies with the aim of validating the technology in preclinical models of different tumors driven by CSCs, and thus facilitate its access to the market. The proposal led by Prof. Mascareñas is one of the five biomedical research projects that have been selected in the second round of this call, at the national level. In addition to receiving a financial support of 300,000€, all of the selected projects will have the help of mentors to define their development and commercialization plans in a personalized way, and expert support in technology transfer, financing tools or negotiations.

Dr. Sainz’s group has generated important advances in the area of cell biology, and is currently exploring ways to alter the metabolic requirements of CSCs. The MetBioCat group led by Prof. Mascareñas is already a reference group in the area of biological chemistry, including the design of ruthenium-based metal complexes that are able to act selectively on DNA. Both laboratories form a multidisciplinary team with extensive experience whose collaboration dates back to an IGNICIA project of the Xunta de Galicia.


Products You May Like

Articles You May Like

Biotech Startup Incubators Prepare to Cash in on Record VC Funding
Multimodal CTC detection using stem cell antigen-specific immunosilica particles and immunofluorescent quantum dots
Novo Nordisk comes out clean in $1.8B investor lawsuit alleging insulin misdirection
SARS-CoV-2 Omicron variant’s infectivity, vaccine breakthrough, and antibody resistance
While Omicron continues to dominate across the world, COVID-19 travel requirements remain

Leave a Reply

Your email address will not be published. Required fields are marked *